Consistent with this, the HERACLES-A trial documented a response rate of 30% in 27 patients with native KRAS CRC, positive HER2, and anti-EGFR resistance treated with lapatinib and trastuzumab [35]. Here, ERBB2 is linked to colorectal carcinoma.